Vienna, Austria – Royal Philips Electronics (NYSE: PHG, AEX: PHI) will showcase respiratory innovations to help manage long term health conditions such as sleep disordered breathing and obstructive and restrictive lung diseases at the 2012 European Respiratory Society (ERS) Annual Congress, the largest scientific meeting for respiratory professionals, 1-5 September in Vienna.
“The ERS 2012 Congress draws global attention to respiratory issues with broad societal and economic implications such as increased morbidity and high health costs,” says Mats Dahlquist, General Manager Philips Home Healthcare Solutions International. “As part of our Allies in Better Sleep and Breathing initiative, we are committed to aligning with clinicians to provide integrated programs and science-based solutions that address rising incidences of obstructive sleep apnea and chronic obstructive pulmonary disease in adults, and asthma and neuromuscular diseases in adults and children, leading to better sleep, easier breathing and healthier lives for people of all ages.”
For more than three decades, healthcare professionals have looked to Philips Respironics for a complete range of therapy solutions, including drug delivery, oxygen therapy and ventilation, to optimize the management of these patients. Philips Respironics is a pioneer in helping improve patient comfort and quality of life through improved therapies using unique clinically proven technologies. During ERS, Philips Respironics will showcase several existing and soon-to-be-released respiratory innovations.
New respiratory range of products unveiled at ERS 2012
The BiPAP A40, a soon to be released bi-level ventilator capable of non-invasive and invasive pressure ventilation for patients suffering from obesity hypoventilation syndrome, COPD or neuromuscular diseases. This ventilator helps paediatric patients and patients with low inspiratory drive, by combining technological and comfort innovations with ease-of-use while increasing patients’ support and mobility.
The CoughAssist E70, a soon to be released mechanical in-exsufflation device, simulates a real cough and helps mobilize patients’ secretions. Just like other Philips Respiratory devices, this portable system will also include full access to patient therapy information that allows the clinician to assess therapy efficacy and make the necessary adjustments.
Sami the Seal, Philips Respironics’ first nebulizer compressor system for children, supports aerosol therapy compliance and encourages children with asthma to take their medication. Sami is paired with the SideStream nebulizer and Tucker the Turtle mask to help parents and caregivers achieve fast and efficient treatments. The device has been developed to withstand frequent use in hospital and is also a robust and reliable option for the home.
The SimplyGo is the first portable oxygen concentrator able to provide pulse-dose and continuous flow oxygen therapy up to 2 liters per minute. It can adapt to most oxygen patients’ needs and weighs only 4.5 kg. SimplyGo enables patients to have the independance too enjoy time away from home.
Philips Respironics showcases sleep-disordered breathing innovations:
Philips Respironics is a pioneer in evidence-based sleep solutions. One of the most common sleep disorders, OSA affects approximately five to six percent of the adult population and two to three percent of children1. It is characterized by episodes of narrowing and closure of the upper airway during sleep, which obstructs breathing. These episodes can be reversed by wearing a Continuous Positive Airway Pressure (CPAP) device during sleep. This treatment provides slightly pressurized air to the patient via a nasal or face mask to hold the upper airway open during sleep. If left untreated OSA may increase the risk of other serious chronic conditions such as diabetes and cardiovascular disease2.
Philips Respironics portfolio of masks is designed for patient comfort and performance. Listening to clinicians and patients, Philips Respironics developed the new soon to be released Amara full-face mask. Amara has an innovative four-part design that is lighter, smaller and requires just a single click to assemble, making it easy to fit and easy for patients to live with.
Enhancements to the System One family of sleep therapy devices have provided one intelligent solution that can help accelerate patient success and establish greater management efficiency. These include the new REMstar Pro with CPAP Check, a sleep therapy device that automatically adjusts the CPAP pressure every 30 hours, with a maximum long term pressure change of +-3 cmH2O, so that treatment follows changes in patients’ conditions.
The REMstar Auto with Auto Trial automatically titrates the therapy pressure and then switches to CPAP check mode. These intelligent solutions may help reduce the number of interventions made by the care team to manage patient therapy. The new heated hose option provides additional humidity for better patient comfort. To help patients better adapt to their treatment, the design has been enhanced so that the device looks less like a medical product and fits better in to the patient’s bedroom.
For effective device therapy to be delivered, continual monitoring of the patient's use and clinical response is of great importance. Philips Respironics provides multiple data transfer and reporting options with its Encore software portfolio for clinicians and specialists to monitor usage and efficacy with ease and cost efficiency. The System One family of devices includes on-board data memory along with advanced wireless M2M technology, which allows for patient data to be either uploaded to one of the Encore desktop software platforms (EncorePro or EncoreBasic), or automatically on a daily basis to a new secured, online platform, EncoreAnywhere.
Additional Philips Respironics activity includes a workshop and demonstration on target tidal volume ventilation for the treatment of hypoventilation during sleep. This workshop takes place on Sunday, 2nd September from 1.15pm - 2.30pm in room C5 and is chaired by Dr. Nick Hart, UK and Dr. Stefano Nava, Italy.